TRAW catalyst calendar

Traws Pharma, Inc.

Upcoming catalysts
3
Phase 3 programs
3

Traws Pharma, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 13, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.

Across 29 concluded trials, 83% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 13, 2026 est. Next quarterly earnings (projected) Earnings —
November 15, 2026 Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model Trial Milestone Phase 2
December 15, 2026 This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza Trial Milestone Phase 2

Track TRAW alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open TRAW in the tracker

Recent history

DateEventTypePhase
September 15, 2026 Study of TRX-100 Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy Volunteers Trial Milestone Phase 1
August 14, 2026 Quarterly results filed (8-K) Earnings —
July 31, 2026 8-K filed: Listing / standard notice Corporate —
July 10, 2026 8-K filed: Other event Filing —
July 9, 2026 8-K filed: Leadership change Corporate —
June 22, 2026 8-K filed: Reg FD disclosure Filing —
June 12, 2026 8-K filed: Reg FD disclosure Filing —
May 27, 2026 8-K filed: Reg FD disclosure Filing —
May 26, 2026 8-K filed: Other event Filing —
May 15, 2026 Quarterly results filed (8-K) Earnings —
April 15, 2026 8-K filed: Material agreement, Other event Corporate —
April 15, 2026 Quarterly results filed (8-K) Earnings —
February 19, 2026 8-K filed: Other event Filing —
February 15, 2026 Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19 Trial Milestone Phase 2
January 26, 2026 8-K filed: Other event Filing —
January 13, 2026 8-K filed: Other event Filing —
December 17, 2025 8-K filed: Other event Filing —
December 16, 2025 8-K filed: Leadership change Corporate —
November 28, 2025 8-K filed: Leadership change Corporate —
November 13, 2025 Quarterly results filed (8-K) Earnings —
October 17, 2025 8-K filed: Leadership change Corporate —
October 14, 2025 8-K filed: Other event Filing —
October 6, 2025 8-K filed: Leadership change, Reg FD disclosure Corporate —
September 12, 2025 8-K filed: Material agreement, Acquisition completed Corporate —
August 18, 2025 8-K filed: Reg FD disclosure, Other event Filing —
August 14, 2025 Quarterly results filed (8-K) Earnings —
July 3, 2025 8-K filed: Leadership change Corporate —
June 30, 2025 8-K filed: Reg FD disclosure, Other event Filing —
June 3, 2025 8-K filed: Reg FD disclosure, Other event Filing —
May 27, 2025 8-K filed: Reg FD disclosure, Other event Filing —

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.